Bank of America faces $250 million annual bill for GLP-1 weight loss drugs

The massive expenditure represents a significant slice of the company’s $2 billion total annual healthcare budget. As demand for popular drugs like Ozempic and Wegovy climbs, the bank is aggressively leveraging its size to negotiate lower pricing from pharmaceutical manufacturers and pharmacy benefit managers. Moynihan remains focused on cost containment, admitting that while the company pushes for the lowest possible rates, the primary goal remains providing a benefit that yields measurable health returns.

To maximize the efficacy of these treatments, the bank pairs medication access with mandatory health coaching. This approach aims to ensure that weight loss is accompanied by sustainable lifestyle adjustments. While some employees may depart the firm before the company realizes the full long-term financial savings of a healthier workforce, leadership maintains that the immediate impact on employee well-being justifies the current financial commitment.